Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy

Journal of Clinical Oncology

Volumn 30, Issue 13, 2012, Pages 1476-1483

  Uldrick, Thomas S ^a   Wyvill, Kathleen M ^a   Kumar, Pallavi ^a   O'Mahony, Deirdre ^a   Bernstein, Wendy ^a   Aleman, Karen ^a   Polizzotto, Mark N ^a   Steinberg, Seth M ^a   Pittaluga, Stefania ^a   Marshall, Vickie ^b   Whitby, Denise ^b   Little, Richard F ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; ANTIRETROVIRUS AGENT; CYTOKINE; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; CELLULITIS; CLINICAL ARTICLE; CLINICAL OBSERVATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; FOLLOW UP; HEADACHE; HEART LEFT VENTRICLE FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED KAPOSI SARCOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTENSION; INFECTION; KAPOSI SARCOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MIDDLE AGED; TIME; TREATMENT OUTCOME; UNITED STATES; VASCULARIZATION; VIROLOGY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTI-RETROVIRAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYTOKINES; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MARYLAND; MIDDLE AGED; SARCOMA, KAPOSI; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84862992764     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6853     Document Type: Article

References (61)

1. Chang Y, Cesarman E, Pessin MS, et al: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869, 1994
2. Whitby D, Howard MR, Tenant-Flowers M, et al: Detection of Kaposi sarcoma associated herpes-virus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346:799-802, 1995
3. Moore PS, Kingsley LA, Holmberg SD, et al: Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS 10:175-180, 1996 (Pubitemid 26056010)
4. Engels EA, Biggar RJ, Hall HI, et al: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123:187-194, 2008 (Pubitemid 351705208)
5. Shiels MS, Pfeiffer RM, Gail MH, et al: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762, 2011
6. Chokunonga E, Levy LM, Bassett MT, et al: AIDS and cancer in Africa: The evolving epidemic in Zimbabwe. AIDS 13:2583-2588, 1999 (Pubitemid 30038037)
7. Mosam A, Carrara H, Shaik F, et al: Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). Int J STD AIDS 20:553-556, 2009
8. Dupont C, Vasseur E, Beauchet A, et al: Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients: CISIH 92 - Centre d'Information et de Soins de l'Immunodeficience Humaine. AIDS 14:987-993, 2000 (Pubitemid 30336059)
9. Noy A, Scadden DT, Lee J, et al: Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: From the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-998, 2005 (Pubitemid 46205948)
10. Krown SE: Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: Implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 22:399-402, 2004
11. Guihot A, Dupin N, Marcelin AG, et al: Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis 194:1078-1088, 2006 (Pubitemid 44547647)
12. Tulpule A, Scadden DT, Espina BM, et al: Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 18:716-723, 2000 (Pubitemid 30106601)
13. Martin-Carbonero L, Barrios A, Saballs P, et al: Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretro-viral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 18:1737-1740, 2004 (Pubitemid 39095795)
14. Northfelt DW, Dezube BJ, Thommes JA, et al: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol 16:2445-2451, 1998 (Pubitemid 28309039)
15. Stewart S, Jablonowski H, Goebel FD, et al: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16:683-691, 1998 (Pubitemid 28135616)
16. Cooley T, Henry D, Tonda M, et al: A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 12:114-123, 2007 (Pubitemid 46143509)
17. Martín-Carbonero L, Palacios R, Valencia E, et al: Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 47:410-417, 2008 (Pubitemid 352009365)
18. Smith LA, Cornelius VR, Plummer CJ, et al: Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337, 2010
19. Yarchoan R, Tosato G, Little RF: Therapy insight: AIDS-related malignancies: The influence of antiviral therapy on pathogenesis and management. Nat Clin Pract Oncol 2:406-415, 2005 (Pubitemid 43115009)
20. Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, et al: Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 8:167-176,2007 (Pubitemid 46158383)
21. Uldrick TS, Whitby D: Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. Cancer Lett 305:150-162, 2011
22. Brown LF, Tognazzi K, Dvorak HF, et al: Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148:1065-1074, 1996
23. Masood R, Cai J, Zheng T, et al: Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 94:979-984, 1997 (Pubitemid 27074433)
24. Bais C, Santomasso B, Coso O, et al: G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391:86-89, 1998 (Pubitemid 28079220)
25. Cannon M, Philpott NJ, Cesarman E: The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 77:57-67, 2003 (Pubitemid 36004946)
26. Aoki Y, Tosato G: Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas. Blood 94:4247-4254, 1999
27. Cai Q, Murakami M, Si H, et al: A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol 81:10413-10423, 2007 (Pubitemid 47463315)
28. Prakash O, Swamy OR, Peng X, et al: Activation of Src kinase Lyn by the Kaposi sarcomaassociated herpesvirus K1 protein: Implications for lymphomagenesis. Blood 105:3987-3994, 2005 (Pubitemid 40656147)
29. Wang L, Wakisaka N, Tomlinson CC, et al: The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. Cancer Res 64:2774-2781, 2004 (Pubitemid 38500615)
30. Aoki Y, Tosato G, Nambu Y, et al: Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas. Blood 95:1109-1110, 2000 (Pubitemid 30062740)
31. Nagy JA, Masse EM, Herzberg KT, et al: Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55:360-368, 1995
32. Nagy JA, Morgan ES, Herzberg KT, et al: Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 55:376-385, 1995
33. Haddad L, El Hajj H, Abou-Merhi R, et al: KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. Leukemia 22:826-834, 2008 (Pubitemid 351552632)
34. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC, Department of Health and Human Services, 2009, pp 1-161
35. Little RF, Pluda JM, Wyvill KM, et al: Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 107:4650-4657, 2006 (Pubitemid 43882610)
36. Krown SE, Metroka C, Wernz JC: Kaposi's sarcoma in the acquired immune deficiency syndrome: A proposal for uniform evaluation, response, and staging criteria - AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 7:1201-1207, 1989 (Pubitemid 19220121)
37. Welles L, Saville MW, Lietzau J, et al: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 16:1112-1121, 1998 (Pubitemid 28108748)
38. Uldrick TS, Wang V, O'Mahony D, et al: An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcomaassociated herpesvirus and HIV but without multicentric Castleman disease. Clin Infect Dis 51:350-358, 2010
39. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
40. Krown SE, Testa MA, Huang J: AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification - AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 15:3085-3092, 1997 (Pubitemid 27377500)
41. Nasti G, Talamini R, Antinori A, et al: AIDS-related Kaposi's sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the HAART era - The Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 21:2876-2882, 2003 (Pubitemid 46621836)
42. Do T, Duncan J, Butcher A, et al: Comparative frequencies of HIV low-level viremia between real-time viral load assays at clinically relevant thresholds. J Clin Virol 52:S83-S89, 2011 (suppl 1)
43. Hsieh MM, Tisdale JF, Rodgers GP, et al: Neutrophil count in African Americans: Lowering the target cutoff to initiate or resume chemotherapy? J Clin Oncol 28:1633-1637, 2010
44. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003 (Pubitemid 36910021)
45. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
46. Burger RA, Sill MW, Monk BJ, et al: Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study. J Clin Oncol 25:5165-5171, 2007 (Pubitemid 350237599)
47. Bower M, Nelson M, Young AM, et al: Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 23:5224-5228, 2005 (Pubitemid 46224033)
48. Leidner RS, Aboulafia DM: Recrudescent Kaposi's sarcoma after initiation of HAART: A manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 19:635-644, 2005 (Pubitemid 41527674)
49. Grove CS, Lee YC: Vascular endothelial growth factor: The key mediator in pleural effusion formation. Curr Opin Pulm Med 8:294-301, 2002 (Pubitemid 34625963)
50. Jain RK, Duda DG, Willett CG, et al: Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338, 2009
51. Sun Q,Matta H, Lu G, et al: Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kappa B activation. Oncogene 25:2717-2726, 2006
52. Lane BR, Liu J, Bock PJ, et al: Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma. J Virol 76:11570- 11583, 2002
53. Gressett SM, Shah SR: Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 43:490-501, 2009
54. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al: Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study - AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 16:1444-1449, 1998 (Pubitemid 28175764)
55. Cianfrocca M, Cooley TP, Lee JY, et al: Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: A phase I AIDS malignancy consortium study. J Clin Oncol 20:153-159, 2002 (Pubitemid 34032606)
56. Dezube BJ, Krown SE, Lee JY, et al: Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: An AIDS Malignancy Consortium Study. J Clin Oncol 24:1389-1394, 2006 (Pubitemid 46622003)
57. Folpe AL, Veikkola T, Valtola R, et al: Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. Mod Pathol 13:180-185, 2000 (Pubitemid 30109106)
58. Skobe M, Brown LF, Tognazzi K, et al: Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol 113:1047-1053, 1999 (Pubitemid 30013351)
59. Marchiò S, Primo L, Pagano M, et al: Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 274:27617-27622, 1999
60. Stürzl M, Brandstetter H, Zietz C, et al: Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: A combined in vitro and in vivo analysis. Oncogene 10:2007-2016, 1995
61. Ganem D: KSHV-induced oncogenesis, in Arvin A, Campadielli-Fume G, Mocarski E, et al (eds): Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge, MA, Cambridge University Press, 2007